"Fenofibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
| Descriptor ID |
D011345
|
| MeSH Number(s) |
D02.241.081.114.968.500.625 D02.355.726.305.625 D02.455.426.559.389.134.750 D02.455.426.559.389.657.654.305.625 D02.522.223.750
|
| Concept/Terms |
Fenofibrate- Fenofibrate
- Phenofibrate
- Procetofene
- Procetofen
Apo-Feno-Micro- Apo-Feno-Micro
- Apo Feno Micro
- Apo-Fenofibrate
- Apo Fenofibrate
Lipanthyl- Lipanthyl
- Lipantil
- Fenofibrat FPh
- Lipidil
- Secalip
- Supralip
- Fénofibrate Debat
- Debat, Fénofibrate
- Lipidil-Ter
- Lipidil Ter
|
Below are MeSH descriptors whose meaning is more general than "Fenofibrate".
Below are MeSH descriptors whose meaning is more specific than "Fenofibrate".
This graph shows the total number of publications written about "Fenofibrate" by people in this website by year, and whether "Fenofibrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 5 | 1 | 6 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fenofibrate" by people in Profiles.
-
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. Med Hypotheses. 2020 Oct; 143:110197.
-
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. Med Hypotheses. 2020 Oct; 143:110127.
-
Drugs linked to plasma homoarginine in chronic kidney disease patients-a cross-sectional analysis of the German Chronic Kidney Disease cohort. Nephrol Dial Transplant. 2020 07 01; 35(7):1187-1195.
-
[Management of hypertriglyceridaemia]. Rev Med Liege. 2019 Mar; 74(3):167-172.
-
Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate. J Assoc Physicians India. 2018 Dec; 66(12):55-57.
-
Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Press Cardiovasc Prev. 2018 Dec; 25(4):355-359.
-
FGF21 mediates the protective effect of fenofibrate against acetaminophen -induced hepatotoxicity via activating autophagy in mice. Biochem Biophys Res Commun. 2018 09 05; 503(2):474-481.
-
Work in Progress: Drugs in Development. Clin Liver Dis. 2018 08; 22(3):501-515.
-
Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. J Cell Biochem. 2018 09; 119(9):7458-7469.
-
PPAR-a Agonist Improves Hyperglycemia-Induced Oxidative Stress in Pancreatic Cells by Potentiating Antioxidant Defense System. Drug Res (Stuttg). 2018 Jun; 68(6):355-360.